Latest Mitochondrial Peptide Research: MOTS-c, SS-31, and Beyond

Mitochondrial peptides are having a moment. The 2025 to 2026 publication window added meaningful mechanistic and clinical data to all three of the main compounds in this class: MOTS-c, SS-31 (also called Elamipretide), and the humanin family. What links these compounds is that they all act at or come from the mitochondria. MOTS-c and humanin are encoded inside mitochondrial DNA (yes, mitochondria have their own DNA). SS-31 is a synthetic tetrapeptide designed to grab onto cardiolipin, a specific lipid in the inner mitochondrial membrane. The 2025 highlight on the clinical side was an Aging Cell paper reporting preserved mitochondrial function markers in aged rodent muscle after MOTS-c administration, plus additional SS-31 Phase II data in primary mitochondrial disease research populations. On the mechanism side, humanin gained new candidate receptor work, and next-generation mitochondrial-targeted peptides started showing up in earlier-stage research. This article walks through what each compound is doing in the current literature, how the new findings extend the older work, and where reviewers say the field still needs to fill in gaps. All findings described are from in vitro, cell culture, rodent, or defined human research trial populations. None of this is clinical advice for human use. MOTS-c, the higher-mass MOTS-c 40mg format, and SS-31 are all supplied at originlabsresearch.com for institutional research-use-only work.

MOTS-c: recent mechanistic and metabolic research

MOTS-c was first described in a 2015 Cell Metabolism paper by Lee and colleagues. It is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA region. The original paper reported metabolic effects in rodent models including improvements in measured insulin sensitivity and reductions in adiposity in diet-induced obesity models. The proposed mechanism then and now centres on AMPK pathway activation. AMPK is the cellular energy sensor that gets switched on when ATP levels drop.

What the 2024 to 2026 publication window added:

• A 2025 Aging Cell paper reported preserved mitochondrial function markers in aged rodent muscle after MOTS-c administration, with associated changes in measured exercise capacity endpoints.
• A 2024 paper explored MOTS-c in a MASLD (metabolic-associated steatotic liver disease) model, reporting changes in hepatic lipid metabolism markers in treated animals versus vehicle controls.
• Pharmacological characterisation advanced with publications investigating circulating MOTS-c concentrations in human research populations and reporting associations with measured exercise performance and metabolic health markers.

For labs running higher-dose model work, the MOTS-c 40mg format is supplied alongside the standard format.

The MOTS-c literature is characterised by a strong preclinical and observational human research base with limited published controlled clinical trial data. Reviewers continue to identify controlled clinical trials as the major next-stage research priority for this compound.

SS-31 (Elamipretide): clinical and preclinical updates

SS-31, also referenced as Elamipretide, is a synthetic tetrapeptide. The sequence is D-arginine, dimethyl-tyrosine, lysine, and phenylalanine. It is designed to associate with cardiolipin in the inner mitochondrial membrane. Cardiolipin is a phospholipid that organises the electron transport chain complexes (the protein machines that produce ATP). The published pharmacology describes SS-31 binding to cardiolipin and stabilising the electron transport chain complexes, with downstream effects on mitochondrial respiration, reactive oxygen species generation, and ATP production reported in cellular and animal model systems.

Where SS-31 stands clinically (more advanced than most mitochondrial peptides):

• Phase II trials reported in primary mitochondrial myopathy research populations.
• Phase II trials reported in heart failure research populations.
• Phase II trials reported in age-related macular degeneration research populations.

What the 2025 to 2026 publication window added:

• Additional Phase II reports and longer-term follow-up analyses from earlier published trials.
• Structural biology data describing the cardiolipin binding mode and the consequences for inner membrane organisation.
• New preclinical model work in ischaemia-reperfusion injury, age-related macular degeneration, and mitochondrial cardiomyopathy models.

Published clinical efficacy data has been mixed across indication areas. The SS-31 literature illustrates the broader challenge of translating mitochondrial-targeted pharmacology from preclinical to clinical settings.

Humanin family research and recent extensions

Humanin is a 24-amino-acid peptide first described around 2001. It is encoded inside the mitochondrial 16S rRNA region. Early work reported cytoprotective effects in cellular models of Alzheimer disease pathology. The family has expanded over two decades to include several derivative peptides with modified sequences and reported pharmacological profiles.

What the 2024 to 2026 publication window added:

• Continued mechanistic exploration of the cytoprotective effects in cell culture stress models.
• Work on the interaction between humanin and the IGF-binding protein system.
• A 2025 paper reported humanin binding interactions with formyl peptide receptors in cell culture systems, with downstream signalling effects described in measured cellular survival endpoints.
• Observational human research papers reporting circulating humanin concentrations and exploring associations with ageing markers, metabolic health markers, and central nervous system endpoints.

No large controlled clinical trials have been published for the humanin family as of the mid-2026 review window. The humanin literature overlaps mechanistically and conceptually with the broader mitochondrial-derived peptide field and is often discussed in the same reviews as MOTS-c.

Next-generation mitochondrial-targeted peptide research

Beyond the three established mitochondrial peptides, the 2025 to 2026 window also covered earlier-stage compounds in development.

Design strategies that showed up in the literature:

• Triphenylphosphonium conjugation (a chemistry trick that uses the mitochondrial membrane potential to concentrate compounds inside mitochondria).
• Mitochondrial penetrating peptide sequences designed to get past the inner membrane.
• Other targeting strategies for specific subcompartments.

Candidate targets covered:

• Cardiolipin.
• Specific electron transport chain complex subunits.
• The mitochondrial permeability transition pore.
• The mitochondrial calcium uniporter.

Mechanistic publications during the period explored design considerations for subcompartmental selectivity, including membrane potential dependence, off-target binding, and translational pharmacokinetics. 2024 to 2025 reviews framed the mitochondrial-targeted peptide field as a research-active area with substantial chemical biology innovation but with the broader translational challenge of moving compounds from cellular and animal model systems into validated clinical indications. Several next-generation compounds have entered early clinical research, with Phase I and Phase IIa data reported in specific indication areas during the recent window.

Clinical translation in this field is generally slower than in the broader peptide drug development space. The technical challenges of subcompartmental targeting and the difficulty of identifying clinical indications with strong mechanistic alignment to a single mitochondrial target are both contributors.

Open questions and implications for investigators

Four recurring open questions across the mitochondrial peptide literature:

• Receptor and target identification. The exact receptor systems through which MOTS-c and humanin signal remain incompletely defined despite extensive pharmacological work. The field continues to publish candidate receptor identifications and refine the mechanistic models.
• Interspecies translation. The overwhelming majority of MOTS-c, humanin, and related publications use rodent models. Translational reliability of the preclinical findings remains an active research question.
• Optimal pharmacological design. The mitochondrial-derived peptides operate through endogenous signalling pathways. Compounds like SS-31 and the triphenylphosphonium-conjugated peptides operate through pharmacological targeting of inner-membrane components. Whether one approach is superior across indication areas remains unresolved.
• Controlled clinical trial evidence base. With the exception of SS-31, the field has limited published controlled clinical trial data. Reviewers continue to identify controlled trials in well-defined research populations as the major next-stage priority.

For investigators planning new preclinical or clinical research in this space, the most recent reviews provide a structured orientation to the open questions and the most informative comparator publications. Compounds in this class supplied at originlabsresearch.com are provided as research material for institutional research-use-only purposes.

References

1. [1] Lee C, Zeng J, Drew BG, Sallam T, Martin-Montalvo A, Wan J, Kim SJ, et al. (2015). The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. PMID 25738459
2. [2] Karaa A, Haas R, Goldstein A, Vockley J, Weaver WD, Cohen BH (2018). Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy. Neurology. PMID 30381366
3. [3] Hashimoto Y, Niikura T, Tajima H, Yasukawa T, Sudo H, Ito Y, Kita Y, et al. (2001). A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer's disease genes and Abeta. Proceedings of the National Academy of Sciences. PMID 11371646
4. [4] Birk AV, Liu S, Soong Y, Mills W, Singh P, Warren JD, Seshan SV, et al. (2013). The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. PMID 23720547
5. [5] Reynolds JC, Lai RW, Woodhead JST, Joly JH, Mitchell CJ, Cameron-Smith D, Lu R, et al. (2021). MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. PMID 33446691

Frequently asked questions